{"activeTab":"all","articleCategories":[{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:34:53 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"new-in-myeloma","sectionConfig":{"news":{"description":"Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.","metaDescription":"It's important for patients to stay up-to-speed on advancements in their cancer because the treatment options are rapidly changing.","metaTitle":"Treatment Advances - HealthTree Foundation","order":1,"tileOrder":1,"type":"LARGE_TILE"}},"sections":["NEWS"],"slug":"treatment-advances","status":"ACTIVE","title":"Treatment Advances","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:03 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"snapshot":{"exists":true,"id":"haqKTOi9lG4MNU3rNLG6","ref":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"}}},{"data":{"createdAt":{"_type":"Date","value":"Sat Jul 30 2022 16:56:14 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"fitness","sectionConfig":{"events":{"description":"Our Navigating Your Health events help you manage your wellness through diet, fitness, side effect management, survivorship, and life hacks that can improve your quality of life.","metaDescription":"Events you can join designed for navigating your health such as infection prevention, battling disparities, and survivorship.","metaTitle":"Navigating Your Health Events - HealthTree","order":1},"news":{"description":"Our Navigating Your Health articles can help you proactively take control of your health through wellness news, financial updates, healthy recipes, and more.","metaDescription":"Learn tips related to your overall wellness, including your mental, physical, and emotional health.","metaTitle":"Navigating Your Health - HealthTree Foundation","order":2},"podcasts":{"order":7,"status":"DRAFT"}},"sections":["EVENTS","NEWS"],"slug":"navigating-your-health","status":"ACTIVE","title":"Navigating Your Health","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:49 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"snapshot":{"exists":true,"id":"hn1DyzeAyX6tgl3gxSDx","ref":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:34:03 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"myeloma-basics","sectionConfig":{"news":{"description":"Our Core Education articles help you understand your cancer so you are equipped to find a good care team, ask appropriate questions, and become your own best advocate.","metaDescription":"Learn 101 Education to help you know more about your cancer, what tests and treatments are available to you, and more.","metaTitle":"Core Education - HealthTree Foundation","order":3,"tileOrder":3,"type":"LARGE_TILE"}},"sections":["NEWS"],"slug":"core-education","status":"ACTIVE","title":"Core Education","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:23 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/MB3xw38fuKkx0LdszsrL"},"snapshot":{"exists":true,"id":"MB3xw38fuKkx0LdszsrL","ref":{"_type":"DocumentReference","path":"apps/community/categories/MB3xw38fuKkx0LdszsrL"}}},{"data":{"createdAt":{"_type":"Date","value":"Wed Jan 04 2023 22:59:47 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"patient-stories","sectionConfig":{"news":{"description":"Our Patient Stories articles contain patient and caregiver experiences, along with their advice for others going through similar circumstances.","metaDescription":"Read patient stories to learn about other’s experiences and what advice they have for people going through similar circumstances.","metaTitle":"Patient Stories - HealthTree Foundation","order":4,"tileOrder":1,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"patient-stories","status":"ACTIVE","title":"Patient Stories","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:43 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/19hxT6XALz8ds00eORms"},"snapshot":{"exists":true,"id":"19hxT6XALz8ds00eORms","ref":{"_type":"DocumentReference","path":"apps/community/categories/19hxT6XALz8ds00eORms"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:36:49 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"research","sectionConfig":{"events":{"description":"Our HealthTree Research events help you learn about the latest research and studies related to your cancer, including interviews with medical specialists.","metaDescription":"Research Events to help you learn about the latest research and studies related to your cancer, including interviews with medical specialists.","metaTitle":"(disease) Research Events - HealthTree Foundation","order":5},"news":{"description":"Our HealthTree Research articles contain findings from surveys and studies inside HealthTree’s database. These surveys and studies are conducted by researchers and specialists.","metaDescription":"These articles are findings from HealthTree Research findings from surveys and studies.","metaTitle":"HealthTree Research - HealthTree Foundation","order":5,"tileOrder":2,"type":"SMALL_TILE"},"podcasts":{"order":2,"status":"ACTIVE"}},"sections":["EVENTS","NEWS"],"slug":"research","status":"ACTIVE","title":"HealthTree Research","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:49 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/BnXIg7Ru4SK5FpscX41b"},"snapshot":{"exists":true,"id":"BnXIg7Ru4SK5FpscX41b","ref":{"_type":"DocumentReference","path":"apps/community/categories/BnXIg7Ru4SK5FpscX41b"}}},{"data":{"createdAt":{"_type":"Date","value":"Sat Dec 02 2023 00:52:31 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"conferences","sectionConfig":{"news":{"description":"Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.","metaDescription":"These articles discuss the latest coverage of medical advancements from recent academic conferences.","metaTitle":"Conferences - HealthTree Foundation","order":6,"tileOrder":3,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"conferences","status":"ACTIVE","title":"Conferences","updatedAt":{"_type":"Date","value":"Fri Apr 12 2024 20:21:44 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"},"snapshot":{"exists":true,"id":"j4bWXiDzhdlhMFvaeXoc","ref":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:12 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"clinical-trials","sectionConfig":{"news":{"description":"Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.","metaDescription":"These articles highlight top clinical trials, their results, and how patients can participate in them.","metaTitle":"Clinical Trials - HealthTree Foundation","order":7,"tileOrder":4,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"clinical-trials","status":"ACTIVE","title":"Clinical Trials","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:47 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/hUncpyMvyuZCF2qvA0Cv"},"snapshot":{"exists":true,"id":"hUncpyMvyuZCF2qvA0Cv","ref":{"_type":"DocumentReference","path":"apps/community/categories/hUncpyMvyuZCF2qvA0Cv"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:26 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"healthtree","sectionConfig":{"news":{"description":"Our HealthTree Programs articles highlight the programs, events, and updates of the HealthTree Foundation.","metaDescription":"These articles highlight the programs, events, and updates of the HealthTree Foundation.","metaTitle":"HealthTree Programs - HealthTree Foundation","order":8,"tileOrder":6,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"healthtree-programs","status":"ACTIVE","title":"HealthTree Programs","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:52 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/WSTraX4hOKp92asdiTHa"},"snapshot":{"exists":true,"id":"WSTraX4hOKp92asdiTHa","ref":{"_type":"DocumentReference","path":"apps/community/categories/WSTraX4hOKp92asdiTHa"}}},{"data":{"createdAt":{"_type":"Date","value":"Thu Jul 07 2022 16:35:51 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/non-hodgkins-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"}],"migratedReason":"global-community","migratedReason2":"fix global-community categories","migratedSlug":true,"oldSlug":"healthtree-press","sectionConfig":{"news":{"description":"Read articles about HealthTree's progress in major media publications in video, online and in newspapers.","metaDescription":"These articles are about HealthTree's progress in major media publications in video, online and in newspapers.","metaTitle":"HealthTree Press - HealthTree Myeloma","order":9,"tileOrder":5,"type":"SMALL_TILE"}},"sections":["NEWS"],"slug":"healthtree-press","status":"ACTIVE","title":"HealthTree Press","updatedAt":{"_type":"Date","value":"Thu Apr 25 2024 18:37:51 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"},"snapshot":{"exists":true,"id":"SOL2ODcbaDI1CazQRbRS","ref":{"_type":"DocumentReference","path":"apps/community/categories/SOL2ODcbaDI1CazQRbRS"}}}],"articlesToDisplay":[{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/Yj5pk904HRNwZA8Wqfcu"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 19:56:09 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fpatient%252520talking%252520with%252520doctor_0369437d-b84e-445c-8f09-7feab22d5f77.png%253Falt%253Dmedia","htmlContent":"

When you've had a bone marrow transplant for AML or MDS, your healthcare team tracks many things - blood counts, medications, side effects... But new research shows that something equally important might be a simple question: \"How would you say your health is overall?\"

A Simple Question With Important Implications

New research presented at the 2024 American Society of Hematology (ASH) meeting reveals that how transplant survivors describe their own health could provide valuable insights for their care team. Dr. Nora Balas from the University of Alabama at Birmingham led this important study looking at patients' health experiences after transplant.

\n
\"We're seeing more patients receiving bone marrow transplants for AML and MDS,\" explains Dr. Balas. \"While this is excellent news, we know that the journey doesn't end with transplant. Understanding how patients experience their health helps us provide better support when they need it.\"
\n

What the Research Found

The study, which included patients from three major medical centers, asked transplant survivors a straightforward question: \"In general, would you say your health is excellent, very good, good, fair, or poor?\"

The findings showed that:

25% of survivors reported their health as \"fair\" or \"poor\"
These patients often needed additional support
Several factors influenced how people rated their health

Understanding What Affects Your Health Experience

The researchers identified several key areas that influenced how patients felt about their health:

\n
Physical Activity: \"We found that exercise plays an important role,\" notes Dr. Balas. \"This doesn't mean you need to run marathons - even gentle movement within your ability can make a difference.\"
\n
\n
Pain Management: How well pain is controlled significantly affects daily life. Your care team wants to know about any pain you're experiencing so they can help manage it effectively.
\n
\n
Mental Health: \"Psychological support is just as important as physical care,\" Dr. Balas emphasizes. \"There's no shame in asking for help when you're feeling overwhelmed.\"
\n
\n
Social and Economic Support: Access to resources and support systems plays a crucial role in recovery.
\n

Why Speaking Up Matters

The research showed that being open about your health experience isn't just about recording information - it helps your care team provide better support. When patients shared that they were experiencing challenges, healthcare providers could step in with additional resources and support.

What This Means for You

If you're recovering from a transplant:

Be honest with your care team about how you're feeling
Don't hesitate to mention challenges, whether physical or emotional
Ask about resources for exercise, pain management, or mental health support
Remember that there's no \"right\" way to feel - everyone's journey is different

Remember, sharing how you feel isn't about judgment - it's about helping your care team provide the best possible support for your unique experience. Watch our full interview with Dr. Balas to learn more about this important research.

Make Your Experience Count

Your journey can help advance blood cancer research and support others. Join HealthTree Cure Hub, our free patient research platform to:

Securely share your experiences and medical records
Contribute to important research that helps improve care for everyone

Join a community dedicated to improving outcomes for everyone affected by AML and MDS.

Create a Cure Hub Account

Source:

Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report

","language":"EN","metaDescription":"New study shows how being open with your care team about your health after bone marrow transplant for AML or MDS can lead to better support and outcomes.","metaTitle":"Your Health Experience After Transplant Matters","publishedAt":{"_type":"Date","value":"Fri May 16 2025 04:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"bone marrow transplant recovery, transplant patient experience, AML transplant outcomes, MDS transplant outcomes, post-transplant health assessment, blood cancer survivor support, transplant patient communication, bone marrow transplant care, AML patient support, MDS patient support, transplant quality of life, blood cancer research participation, post-transplant care team, bone marrow transplant survival, blood cancer patient community, patient reported outcomes, HealthTree research platform","slug":"speaking-up-health-after-transplant-research","status":"ACTIVE","title":"Speaking Up About Your Health After Transplant: New Research Shows Why It Matters","updatedAt":{"_type":"Date","value":"Fri Apr 18 2025 20:14:05 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/SUmRFpDOhBXIc7yoYVQM"},"snapshot":{"exists":true,"id":"SUmRFpDOhBXIc7yoYVQM","ref":{"_type":"DocumentReference","path":"apps/community/articles/SUmRFpDOhBXIc7yoYVQM"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Tue Apr 22 2025 21:26:07 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fnew%252520medication_f4aa821d-4fe1-4dd5-87c9-007bae7ed4c4.jpg%253Falt%253Dmedia","htmlContent":"

Revumenib (Revufori) is a new medication recently approved for relapsed/refractory acute leukemia patients with the KMT2A translocation. Including both adult and pediatric patients one year and older.

However, there is still ongoing research with revumenib, which we will review in this article. These updates were presented at the 66th annual ASH conferences, where we interviewed lead researchers to bring you all the details you need to know!

To learn more about other menin inhibitors, you can read our previous article: Menin Inhibitors: A New Treatment Option for Some Leukemia Patients

How Revumenib Works

Revumenib is a potent, oral, selective inhibitor of menin (a tumor suppressor protein). It prevents menin from binding to the KMT2A gene.

Revumenib in an All-Oral Treatment Combination for Children Over 12 and Adults

We’ll first review the phase I/II study of revumenib with decitabine/cedazuridine and venetoclax (the SAVE study) in relapsed/refractory AML (NCT05360160).

This trial allowed patients older than 12 years old to participate, but the study is still ongoing. The median age was 35 years (range, 12-79 years), including 5 children. Patients received ASTX727 (decitabine/cedazuridine): 35 mg/100 mg PO daily on days 1-5, and venetoclax: 400 mg PO daily on days 1-14. Revumenib doses varied between patients to find the one that works best.

The Study Results

The overall response rate was 88%, with 74% achieving MRD negativity
Twelve patients were able to undergo stem cell transplant
Six months after starting treatment with revumenib, 59% were in remission, and 74% were alive

Most common side effects included alterations in the electrocardiogram (QT prolongation in 58% of patients), liver enzyme elevation, and low white blood cell counts with fever (febrile neutropenia).

These promising results support further investigation in newly diagnosed patients.

An Ongoing Study for Relapsed/Refractory Acute Leukemias

The AUGMENT-101 Phase 2 study is an ongoing trial that evaluates revumenib, a selective menin inhibitor, as a treatment for relapsed or refractory acute leukemias with KMT2A rearrangements (KMT2Ar). The study represents the largest evaluation of menin inhibition in this patient population to date.

A total of 116 patients received at least one dose of revumenib; 24% of patients were pediatric. Among 97 evaluable patients, the study demonstrated promising response rates and MRD negativity:

The overall response rate was 64%
23% of patients achieved complete remission that lasted for at least 2 months, and for the majority, more than 6 months
58% of all responders achieved MRD negativity
Of those responding to the treatment, 34% of patients could receive a stem cell transplant after therapy, and nine patients resumed revumenib treatment as maintenance

The most common severe side effects were febrile neutropenia, anemia, and low platelet counts. Investigators are also closely monitoring patients who can experience differentiation syndrome (15%) and alterations in their heartbeat (13%).

Final Thoughts

The latest research on revumenib highlights significant progress for relapsed/refractory acute leukemia with KMT2A rearrangements. Offering the potential for patients to undergo curative treatments like stem cell transplantation. However, research is ongoing, and continued patient participation in trials is essential to compare revumenib to other standard treatments and study long-term outcomes.

Your participation in clinical trials might not only offer you access to cutting-edge treatments but also contribute to improving care for future patients. That’s why HealthTree helps you every step of the way with the multiple free resources Cure Hub Registry offers, like exploring personalized clinical trial options, tracking labs and past treatments, and so much more!

Join Cure Hub Now

Empower yourself! Both patients and caregivers can take charge of their treatment and care by staying informed. Click here to read more exciting Leukemia news!

","language":"EN","metaDescription":"Learn about the latest research on revumenib for relapsed/refractory leukemia, including clinical trial results and the importance of patient advocacy.","metaTitle":"Revumenib for Relapsed/Refractory Leukemia Updates","publishedAt":{"_type":"Date","value":"Mon May 12 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"revumenib, relapsed leukemia, refractory leukemia, KMT2A rearrangement, AML treatment, ALL treatment, leukemia clinical trials, menin inhibitor, targeted therapy, MRD negativity, stem cell transplant, leukemia research, AUGMENT-101 trial, INTERCEPT trial, SAVE trial","slug":"revumenib-updates-for-leukemia","status":"ACTIVE","title":"Latest Updates of Revumenib for Acute Leukemia","updatedAt":{"_type":"Date","value":"Mon May 12 2025 21:37:17 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/AzCWT006O9ZJAhcIRhkW"},"snapshot":{"exists":true,"id":"AzCWT006O9ZJAhcIRhkW","ref":{"_type":"DocumentReference","path":"apps/community/articles/AzCWT006O9ZJAhcIRhkW"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Tue May 06 2025 21:33:43 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fsubstance%252520use%252520and%252520cancer_a359ae33-cbc9-4bea-bf38-2a487337461a.jpg%253Falt%253Dmedia","htmlContent":"

Cancer can be physically and emotionally demanding. For some people, this can also put them at risk of substance use. May is the Mental Health Awareness month and in this article we break down how substance use can affect cancer outcomes and explore how stigma can get in the way of care. You’ll also learn how treatment approaches can better support patients managing both cancer and substance use.

Substance Use Is Often Overlooked in Cancer Care

As cancer treatments improve, more patients are living longer. However, mental health and substance use care often remain under-prioritized in oncology. There is a link between substance use and cancer that cannot be overlooked as it goes both directions. Meaning that substance use can increase the risk of certain cancers, and a cancer diagnosis can also trigger or worsen substance use as patients manage pain or emotional distress.

In one study from JAMA Oncology involving over 6,000 adult cancer survivors, 3.83% had an active substance use disorder (SUD), with alcohol use disorder being the most common at 2.78%. This matters because patients with a SUD may receive less effective pain management and face more challenges following their cancer treatment plans. These difficulties can reduce quality of life and lower the chance of recovery.

Why Cancer and Substance Use Often Overlap

A cancer diagnosis often brings physical pain, stress, anxiety, and depression. To cope, some patients turn to alcohol, smoking, or other substances. Pain is commonly treated with opioids, which can be effective but also carry a risk of developing opioid use disorder (OUD).

To read more about opioid use and pain in cancer, visit this article of HealthTree Research findings by clicking the button below.

Managing Pain and Opioid Use for Myeloma Patients

Tobacco and alcohol are the most widely used substances that raise cancer risk.

\n
Tobacco causes about 30% of all cancer deaths, including 80% of lung cancer deaths. It is also linked to cancers of the mouth, throat, larynx, esophagus, stomach, colon, rectum, pancreas, liver, kidney, bladder, cervix, and even blood cancers. Tobacco not only increases the risk of cancer, but can also produce metabolic and circulation issues in the body that make receiving cancer treatment more challenging.
\n
\n
Alcohol is responsible for about 3.5% of cancer deaths. The risk is proportional to the intake; higher amounts over long periods pose a higher risk. For women, heavy use means more than 4 drinks per day or 8 per week. For men, it’s more than 5 drinks per day or 15 per week. Alcohol is processed by the liver and can interfere with the metabolism of other cancer treatments, increase the risk of worse side effects, and, in some cases, inactivate the medication.
\n

These facts are important because quitting tobacco and reducing alcohol use, even after a cancer diagnosis, can still lower future cancer risks and improve health.

Other Substances That Can Complicate Cancer Treatment and Health

Aside from tobacco and alcohol, the following substances are also frequently seen among patients and can interfere with treatment:

\n
Cannabis or marijuana is a natural opioid that can be synthesized into CBD. It can be prescribed by a doctor and administered under controlled conditions. Medical-grade marijuana has strict sanitary regulations and can be beneficial for many people. There is a risk of fungal infection of the lungs associated with marijuana produced in unofficial or unsanitary settings. You can read more about safe uses of cannabis and its risks from the American Thoracic Society here.
\n

\n
Anabolic steroids are the most commonly used drugs among athletes to improve physical performance and aesthetic appearance. These drugs interact with hormone cycles and can also have a negative impact on other organs such as the liver, the cardiovascular, central nervous, musculoskeletal, endocrine, and reproductive systems. It is important to note that anabolic steroids are different from the commonly used steroids in cancer treatments.
\n
\n
Injection drugs, including heroin. These drugs are administered directly into the veins, and their use has risks besides addiction. They can cause vascular strokes, blood and tissue infections, and blood-transmitted diseases like hepatitis and HIV.
Prolonged use can affect the main veins, limiting the option for intravenous cancer medications or increasing the need for longer hospital stays to monitor its applications.
\n
Synthetic drugs, such as methamphetamine (“meth” or “crystal”) is associated with liver cancer and affects psychiatric and physical performance. It is a toxic chemical substance for multiple organs, including the heart, brain and other liver.
\n
Cocaine is a powder absorbed by the mucous membranes. While cocaine’s impact on cellular processes is not fully understood, researchers speculated that the drug might stimulate white blood cell activity and growth. This could potentially speed up the formation of genetic errors that could lead to cancer. Read more about the link of cocaine and cancer here.
\n

Each of these substances has harmful effects on the body in more than one way. For example, meth, heroine and cocaine are often mixed with other toxic chemicals and powders such as benzene, a known carcinogen. All of these substances, once they’ve entered the body, are processed for elimination, interfering with the proper functioning of organs and metabolism. When receiving cancer treatment, they can also interfere with the absorption and beneficial effects of the therapy.

Challenges in Coordinating Cancer and SUD Treatment

Treating cancer and SUD at the same time is complex. Some medications used to treat SUD, like buprenorphine or methadone, can interfere with cancer pain treatments or may be stopped when patients begin cancer care. Conversely, untreated SUD can make it harder to manage symptoms or keep up with appointments.

Patients taking naltrexone for alcohol use disorder may not be able to use certain cancer pain treatments that act on the same parts of the brain.

How Does Stigma Affect People With Substance Use Disorders?

Patients with past or current substance use may fear judgment or treatment changes if they disclose their use. This stigma can prevent honest conversations with their medical team. Feeling stigmatized can reduce the willingness of individuals with SUD to seek treatment.

Stigma remains a major barrier. Some healthcare providers are not trained to manage SUDs in cancer patients, leading to missed opportunities for care. Stigmatizing language and views can negatively influence health care provider perceptions of people with SUD, which can impact the care they provide.

Reducing Stigma and Improving Support

One approach that has shown great results is harm reduction. This means supporting patients in reducing risky behaviors without judgment. For example, rather than requiring someone to fully quit a substance, providers can offer ways to reduce harm while continuing cancer treatment. These can include safer use tips, mental health support, or starting SUD treatment when the patient is ready.

When harm reduction strategies are used with all patients, stigma can be reduced, and more people feel safe sharing their needs.

The way we name things impacts stigma around substance use disorders

There is a story behind every person, some wording perceived as popular, common or “harmless” can stigmatize people living with substance use disorders and prevent them for receiving the care they need. Reducing the stigma can start with simple things such as how we name things.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n Preferred terms that do not stigmatize \n	\n Common terms that might stigmatize \n	\n Why change the language we use? \n
\n Person or patient *with* a: \n \n \n Substance use disorder \n \n \n Opioid use disorder \n \n \n Alcohol use disorder \n \n \n	\n Someone who is a/an: \n \n \n Junkie \n \n \n Addict \n \n \n Alcoholic \n \n \n	\n \n \n Person-first language \n \n \n Demonstrates a person “has” a problem, rather than “is” the problem \n \n \n Avoids negative associations or personal blame \n \n \n
\n \n \n Use (illicit substance) \n \n \n Misuse (prescription medications) \n \n \n	\n \n \n Substance abuse \n \n \n	\n \n \n “Abuse” is associated with negative judgments and punishment \n \n \n
\n \n \n Substance-free \n \n \n Expected/unexpected findings \n \n \n	\n \n \n Clean or dirty \n \n \n Positive/negative \n \n \n	\n \n \n Preferred terms are clinically accurate, non-stigmatizing \n \n \n
\n \n \n Recovery \n \n \n Remission \n \n \n Substance-free \n \n \n	\n \n \n Clean \n \n \n Sober \n \n \n	\n \n \n Preferred terms are clinically accurate and non-stigmatizing, similar to other medical conditions \n \n \n
\n \n \n Addiction \n \n \n	\n \n \n Habit \n \n \n Behavior \n \n \n	\n \n \n Substance use disorders are medical conditions \n \n \n “Habit” or “behavior” is inaccurate and implies control \n \n \n

Chart from Addiction in Patients With Cancer: Challenges and Opportunities

Sourced from National Institute on Drug Abuse (2020)

Moving Toward More Inclusive, Effective Cancer Care

Patients with cancer who also use substances deserve care that addresses all aspects of their health. Integrating addiction services into cancer centers and training oncology providers in harm reduction and substance use management are important next steps.

Better education, open communication, and a compassionate approach can improve outcomes and make sure no patient feels left behind. Substance use is not a failure; it’s a health issue that deserves understanding and treatment, especially during cancer care.

Stay tuned for more articles at the HealthTree News Site, where we publish a wide variety of topics, from conference updates to treatment innovations. Click the button below to keep reading more articles.

For more information and help for people with substance use disorders, you can visit the following assistance resources:

SAMHSA - Substance Abuse and Mental Health Services https://www.samhsa.gov/

Medication Assistance Therapy Care Clinic https://www.matcareclinics.com/

American Addiction Centers https://drugabuse.com/addiction/health-issues/cancer/

CDC Mental Health Resources https://www.cdc.gov/mental-health/caring/index.html#:~:text=Key%20points,to%20the%20nearest%20crisis%20center.

American Society of Addiction Medicine https://www.asam.org/

Start Your Recovery Organization https://startyourrecovery.org/experiences/co-occurring-disorders

Sources:

","isBmh":true,"language":"EN","metaDescription":"Learn how substance use affects cancer care and why reducing stigma improves treatment outcomes for patients with both conditions.","metaTitle":"Improving Care for Cancer and Substance Use","publishedAt":{"_type":"Date","value":"Wed May 07 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"cancer and substance use, cancer addiction care, substance use disorder cancer, cancer stigma, cancer and alcohol, tobacco cancer risk, opioids in cancer, SUD in cancer patients, addiction and oncology, cancer pain management, harm reduction cancer, cancer mental health, alcohol use disorder, cancer coping strategies, integrated cancer care","slug":"improving-care-for-substance-use-and-cancer","status":"ACTIVE","title":"How Substance Use Impacts Cancer Care: Breaking the Stigma to Improve Patient Outcomes","updatedAt":{"_type":"Date","value":"Tue May 13 2025 15:07:22 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/qY2x4G8zjb2zQdVxnObq"},"snapshot":{"exists":true,"id":"qY2x4G8zjb2zQdVxnObq","ref":{"_type":"DocumentReference","path":"apps/community/articles/qY2x4G8zjb2zQdVxnObq"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Wed Apr 23 2025 20:02:38 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_1217522728_4398b480-8204-43d0-be97-b3a5d21354c3.jpg%253Falt%253Dmedia","htmlContent":"

Medical researchers at MD Anderson Cancer Center are conducting a significant clinical trial exploring an innovative strategy: combining a newer targeted therapy, venetoclax (Venclexta, AbbVie), with traditional chemotherapy medications in younger patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). With nearly 100 participants enrolled so far, this ongoing Phase II trial set out to answer a crucial question: could this combination approach improve outcomes for patients who historically faced challenging prospects?

The interim results, which include both short-term responses and early long-term survival data, offer valuable insights for patients and healthcare providers considering their treatment options. The findings summarized below are particularly relevant for those who might be candidates for subsequent stem cell transplantation, a potentially curative procedure for these blood cancers.

Ongoing Study Shows High Remission Rates in Younger AML Patients

The phase II ongoing trial (NCT02115295) enrolled 95 patients with a median age of 49 years old who were newly diagnosed with:

Acute myeloid leukemia (90%)
Mixed phenotype acute leukemia (3%)
High-risk myelodysplastic syndrome (7%)

We had the opportunity to interview the lead investigator of this study, Dr. Tapan Kadia, who shared insights into the study results.

How Effective Was the Combination?

Patients received one to six cycles, with a median of one cycle required to achieve remission
93% of patients achieved a complete response
Overall response rate of 95%
82% of AML patients who achieved a composite complete response were also MRD negative
For AML, the relapse-free survival was 78% at one year, and for MDS, it was 86%
The 2-year probability of survival was estimated at 73% for AML and 100% for high-risk MDS patients

What Were the Most Common Side Effects?

All patients experienced low blood counts during treatment, which is expected with intensive chemotherapy. This led to:

Neutropenic fever (high temperature due to very low white blood cell counts) in about 8 out of 10 patients
A recovery period of approximately 4 weeks for blood counts to return to safer levels
Need for close monitoring and supportive care during this time

Other significant side effects included:

Infections: About 3 in 10 patients developed bloodstream infections, and 2 in 10 developed pneumonia
Gastrointestinal: About 1 in 7 patients experienced inflammation of the bowel (colitis)
Liver: Some patients showed temporary changes in liver function tests

Importantly, despite these side effects, the treatment was generally manageable with proper medical care, with very low treatment-related mortality (2% within the first two months). Patients received preventive medications and growth factors to help manage these side effects.

The Importance of New Treatment Combinations

Using new treatment combinations can increase the number of patients with different diagnoses who can receive a treatment that quickly and effectively controls their cancer cells.

The combination of venetoclax with CLIA chemotherapy demonstrated high effectiveness in younger patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. It offered participants the chance to achieve a deep response and proceed to allogeneic stem cell transplantation. This combination also could offer a long-term durability of response, with an estimated four-year overall survival rate of 71% in patients with newly diagnosed acute myeloid leukemia.

These findings highlight the potential of CLIA-venetoclax as a powerful induction therapy that offers deep and sustained remissions in high-risk patients.

To keep reading more articles like this one, you can browse our HealthTree News section, where you’ll find different article categories.

CONTINUE READING NEWS

Source:

\n
A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
\n

","language":"EN","metaDescription":"The CLIA-venetoclax regimen achieves over 90% response in AML & MDS patients, with high survival rates and low early mortality.","metaTitle":"CLIA-Venetoclax Shows High Response in AML & MDS","publishedAt":{"_type":"Date","value":"Tue May 06 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"CLIA venetoclax, acute myeloid leukemia treatment, high-risk MDS, AML survival rates, AML clinical trial, venetoclax chemotherapy, AML remission, CLIA chemotherapy, AML prognosis, venetoclax combination therapy","slug":"ash-24-clia-venetoclax-aml-mds","status":"ACTIVE","title":"Combining New and Traditional Therapies for AML and MDS Treatment ","updatedAt":{"_type":"Date","value":"Wed May 07 2025 23:30:39 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/ITnmaNWNRUv9r2s5eKnC"},"snapshot":{"exists":true,"id":"ITnmaNWNRUv9r2s5eKnC","ref":{"_type":"DocumentReference","path":"apps/community/articles/ITnmaNWNRUv9r2s5eKnC"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 19:03:22 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_2139857171_d14928f5-f612-4043-98be-81af536978c2.jpg%253Falt%253Dmedia","htmlContent":"

As part of Mental Health Awareness Month, we’ll cover the causes, symptoms, and ways to manage brain-related side effects (difficulty thinking, headaches, etc.) that can happen from blood cancer treatment.

How Blood Cancer Treatments and Other Risk Factors May Impact Brain Function

Several factors can contribute to changes in brain function as a result of blood cancer treatment.

The treatments themselves, like chemotherapy, targeted therapy, radiation, and immunotherapy, can affect brain health by:

Crossing the barrier that protects your brain and directly impacting brain cells.
Triggering inflammation through immune system activation, which clouds brain function.
Remaining oxidative stress after treatment—caused by too many free radicals and not enough antioxidants—can damage healthy cells and trigger inflammation, affecting areas like the brain.

Factors That Increase Your Risk

Having certain health conditions before starting blood cancer treatment can raise the risk of brain-related side effects afterward. These include past cognitive issues (memory loss or trouble concentrating), anemia, mood disorders, chronic stress, hormone imbalances, high blood pressure, poor sleep, nutrient deficiencies, diabetes, systemic inflammation, or recurring infections, among others.

Even without treatment, cancer cells can increase inflammation in the body, which may dampen brain function.

What Do Symptoms Look Like?

The brain-related symptoms you may experience from certain blood cancer treatments may include:

Mild to moderate symptoms: trouble thinking clearly, confusion, fatigue, headaches
More serious issues (rare): difficulty speaking, tremors, seizures

These symptoms are sometimes called chemo brain, brain fog, cognitive impairment, neurological issues, or ICANS (immune effector cell-associated neurotoxicity syndrome). They can be short-term or last longer, but in either case, it is important to communicate with your care team if you are experiencing any of these symptoms for the first time or if they are worsening.

Tips for Recovery

If your brain-related symptoms aren’t improving over time, it’s important to get help. Here are some supportive strategies:

Consult with your blood cancer specialist: Talk to your doctor about ways to manage treatment side effects. For example, if you're experiencing headaches from a cancer therapy, ask what can help. They might recommend adding a headache-relief medication, adjusting the dose, or switching to a different treatment.
Nutrition support: Work with a registered dietitian to reduce inflammation and address nutrient gaps that directly impact brain health.
Visit a functional neurologist: See a functional neurologist who can pinpoint which areas of your brain need support and create a personalized therapy plan using targeted eye, hand, or balance exercises to help strengthen them. They may also suggest adding certain medications. This differs from a neurologist, who focuses mostly on medication to treat symptoms.
Mental health support: A licensed therapist can help you manage stress, anxiety, or trauma, and teach coping skills—like mindfulness and breathing techniques—that may reduce inflammation and improve your quality of life.
Lifestyle habits: Getting enough sleep, staying hydrated, exercising moderately, and eating nutrient-dense foods can support brain health.

Coping support: As you work to regain full cognitive function, tips like using a planner, taking frequent breaks, and doing brain-stimulating activities like puzzles or reading can help you support yourself during recovery.

Key Takeaways

Brain-related side effects from blood cancer treatments can occur and range from mild brain fog to more serious neurological issues.

While these changes can be influenced by the treatments themselves and pre-existing health conditions, there are several supportive strategies—from nutrition and functional neurological therapy to mental health care and lifestyle habits—that may help manage symptoms and promote recovery.

Even if side effects are expected, working closely with your care team is key to finding the right solutions for your cognitive health and overall well-being.

Discover Patient-Reported Side Effect Solutions

Want to share side effects you've experienced during treatment and what helped you manage them? Or curious about what’s worked for other patients? Use HealthTree’s patient-reported side effect solutions tool to learn and contribute below!

Access Side Effect Solutions

!AD!

Sources:

","language":"EN","metaDescription":"In this article, learn about the the causes, symptoms, and ways to manage brain-related side effects that can happen from blood cancer treatment.","metaTitle":"Managing Brain Side Effects of Cancer Treatments","publishedAt":{"_type":"Date","value":"Mon May 05 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"brain fog from blood cancer treatment, chemo brain symptoms, blood cancer cognitive side effects, how cancer affects brain function, managing brain fog in cancer patients, cognitive recovery after chemotherapy, brain health during cancer treatment, neurological side effects of blood cancer, tips for chemo brain recovery, functional neurology for cancer patients, ICANS, HealthTree","slug":"brain-side-effects-causes-management-blood-cancer","status":"ACTIVE","title":"Understanding and Managing Brain-Related Side Effects of Blood Cancer Treatments","updatedAt":{"_type":"Date","value":"Tue Apr 29 2025 17:25:44 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/mk2hzNiMa3G3NzVStboq"},"snapshot":{"exists":true,"id":"mk2hzNiMa3G3NzVStboq","ref":{"_type":"DocumentReference","path":"apps/community/articles/mk2hzNiMa3G3NzVStboq"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/kri5EhhLYvCBbvzzigUx"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Fri May 02 2025 22:32:35 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/E7FvorVuNJjGzy9wH7fy"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FGavel_78d0abbb-cb98-455e-8a89-f671a8a47449.jpg%253Falt%253Dmedia","htmlContent":"

On April 30, 2025, the United States Senate Appropriations Committee gathered for a hearing to discuss the future of federal funding for biomedical research in the United States. This session engaged a variety of voices from committee members, physicians, patients, caregivers, and advocates.

The Committee's main responsibility is to distribute federal funds that ensure that agencies like the FDA and the NIH have the necessary resources to drive scientific discoveries.

During the hearing, several experts and advocates testified, sharing their views on the benefits of federal funding and the urgent need for continued investment in life-saving research.

Federal Funds Advance Discovery, Save Lives, and Offer Hope

For many years, the U.S. has prioritized biomedical research, trained the next generation of scientists, and accelerated the pace of disease-curing discoveries. In the last 30 years, cancer death rates have dropped by 34%. These improvements are a direct result of federally funded programs devoted to cancer prevention, early detection, and advancing treatment options.

Maintaining strong federal support allows researchers to keep making progress, develop new treatments faster, and expand access to clinical trials for patients across the country.

There was strong support from both political parties in attendance for maintaining—and not cutting—federal funding for biomedical research. Legislators on both sides agree that continued federal support is essential for helping agencies like the NIH and FDA build on past achievements and address pressing health challenges.

Committee Chair Susan Collins (R-ME) pointed out that the FDA has approved over 600 cancer treatments because of years of government-supported research. Agencies will need continued funding to build on this progress.

Senator Tammy Baldwin (D-WI) spoke about the long-term impact of cutting biomedical research funding, highlighting that cuts will likely lead to fewer medical student acceptances and research positions, slowing progress in finding new treatments.

Emily Stenson, a pediatric cancer advocate, shared her daughter Charlie’s experience with cancer and emphasized that federal funding for clinical trial research has given her family the hope that she believes every family facing a cancer diagnosis deserves. “Hope gets you through the hardest days. Sometimes hope is all you have. We need to be able to provide that to all families”.

Investing in Innovation and Public Health

Continued investment in health agencies promises not only medical advancements but also helps grow the economy and improve public health outcomes. The Committee’s discussion shows a strong commitment to advancing biomedical research and ensuring that the United States remains a leader in scientific innovation.

How You Can Help Advance Research Through Your Experience

In addition to federal funding, progress in cancer research also depends heavily on understanding the real-world experiences of people living with blood cancer. Your voice can directly shape the future of blood cancer treatment.

By using tools like HealthTree Cure Hub®, you can complete short yet impactful surveys about your diagnosis, treatments, and side effects. This information helps speed up research and leads to more personalized and effective care.

Click the buttons below to access these simple surveys and to learn the results of past patient-accelerated research.

Make an Impact with Brief Blood Cancer Surveys

News Updates on Real-World Research

Sources:

","language":"EN","metaDescription":"Learn how federal funding for cancer research drives progress in treatments, survival rates, and early detection, giving hope to millions of patients","metaTitle":"Federal Funding Fuels Cancer Research ","publishedAt":{"_type":"Date","value":"Fri May 02 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"federal funding for cancer research, biomedical research funding, NIH cancer research, cancer treatment funding, cancer prevention programs, cancer clinical trials, funding cuts to cancer research, cancer survival rates, Senate biomedical funding, future of cancer research funding, healthtree","slug":"federal-funding-for-cancer-research","status":"ACTIVE","title":"Senate Committee Champions Biomedical Research Funding that Advances Cancer Care","updatedAt":{"_type":"Date","value":"Fri May 02 2025 22:11:18 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/R9AORqk6mKOnF1sFA21j"},"snapshot":{"exists":true,"id":"R9AORqk6mKOnF1sFA21j","ref":{"_type":"DocumentReference","path":"apps/community/articles/R9AORqk6mKOnF1sFA21j"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/kri5EhhLYvCBbvzzigUx"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Thu May 01 2025 02:36:41 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FMental%252520Health%252520Awareness%252520Month_2bbf4429-2ff5-4c1c-91dc-f1038f147674.jpg%253Falt%253Dmedia","htmlContent":"

May is Mental Health Awareness Month

This month, HealthTree is sharing insights, tools, and resources to help patients and caregivers better understand how blood cancer impacts mental health and what can be done to improve it at every stage of diagnosis, treatment, and survivorship.

The prevalence of depression and anxiety among individuals diagnosed with cancer is increasing

Studies show that 35–40% of people with cancer have a diagnosable mental health condition. Despite this, patients remain underdiagnosed and undertreated due to a variety of barriers such as:

Stigma around mental health,
Lack of routine mental health screening in oncology settings, and
Limited access to specialized psychological support.

There are a range of factors that impact mental health during cancer treatment, such as the type of cancer, the therapy used, cancer stage, personal support systems, and access to mental health resources. A person’s emotional well-being can shift depending on where they are in their care process and how their body responds to treatment.

People with cancer are more likely to experience depression and anxiety than the general population

Two of the most common mental health conditions in people with cancer are:

Depression-characterized by loss of interest and a lasting feeling of sadness. A person with depression may have fatigue, trouble concentrating, difficulty sleeping, or irritability.
Generalized Anxiety Disorder-characterized by intense feelings of restlessness, tension, uneasiness, or a constant sense of dread. These symptoms are different from the occasional worry or fear.

While the severity of symptoms can vary from person to person, there are common signs that could indicate that a person is experiencing one of these mental health conditions. Left untreated, depression and anxiety can severely disrupt a person's day-to-day activities and reduce overall well-being. However, with the right support, these challenges can be managed over time.

Many factors contribute to the poor identification and treatment of mental health conditions

Stigma around mental health conditions can have a significant influence on whether a person receives the care they need. Fear of judgment may prevent people from openly sharing about their mental health symptoms with family, friends, and providers.

Additionally, in cancer care, a lack of routine screening and standardized testing to properly identify mental health conditions can make receiving the right mental health care difficult for people at different times while living with cancer.

Even when a mental health condition has been identified, people living with cancer face barriers such as long wait times, high treatment costs, limited insurance coverage, or a lack of available providers and resources. These challenges make it even more important for blood cancer care teams to prioritize emotional well-being as part of a treatment plan.

Addressing mental health challenges improves outcomes

Recognizing these symptoms early can help individuals get the help they need sooner and have a positive impact on treatment outcomes. Patients who receive emotional support often experience better treatment adherence, improved quality of life, and reduced symptoms of depression and anxiety, which leads to better overall outcomes.

Mental health treatment is just as important as treating the physical aspects of blood cancer

This month, and every month, HealthTree is committed to providing education, resources, and support to empower patients to seek care for both their bodies and minds.

Many techniques can improve how a person feels and functions throughout cancer treatment.

Explore practical tools and resources you can use to improve mental health:

You can read more about protecting your mental health by clicking the button below:

Protecting Your Mental Health

In addition to seeking care from a mental health professional, you can also find support through HealthTree’s Coach program, where you will be connected with an experienced patient or caregiver who can help you navigate your blood cancer diagnosis.

Connect With A Coach

Help is always available

If you or someone you know is having thoughts of self-harm or suicide, help is available. For immediate assistance, call the 988 suicide & Crisis Lifeline toll-free at 988 or 1-800-273-TALK (8255). You can also text the Crisis Text Line (Hello to 741741) or message the Lifeline Chat on the 988 Suicide & Crisis Lifeline Website.

Source:

Mental health needs in cancer – a call for change

","language":"EN","metaDescription":"Understand how blood cancer impacts mental health and discover ways to improve support during Mental Health Awareness Month","metaTitle":"Blood Cancer and Mental Health Support","publishedAt":{"_type":"Date","value":"Thu May 01 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"blood cancer and mental health, mental health support, blood cancer and depression, blood cancer and anxiety, blood cancer treatment support, cancer mental health statistics, psychological effects of blood cancer, cancer support resources, blood cancer emotional health, HealthTree","slug":"blood-cancer-and-mental-health-support","status":"ACTIVE","title":"Mental Health Awareness Month: Improving Mental Health Among Blood Cancer Patients","updatedAt":{"_type":"Date","value":"Wed May 14 2025 22:42:48 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/q09RwwQn4LEB6AwTRdY6"},"snapshot":{"exists":true,"id":"q09RwwQn4LEB6AwTRdY6","ref":{"_type":"DocumentReference","path":"apps/community/articles/q09RwwQn4LEB6AwTRdY6"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/Y1TeubuOek8X0mlZ691N"},"category":{"_type":"DocumentReference","path":"apps/community/categories/MB3xw38fuKkx0LdszsrL"},"createdAt":{"_type":"Date","value":"Wed Apr 30 2025 00:03:09 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_2152049603_213e8387-794e-4c74-9173-849bac13b937.jpg%253Falt%253Dmedia","htmlContent":"

People living with blood cancer may receive corticosteroids (sometimes referred to as steroids) as part of their treatment plan. In this article, you will learn how corticosteroids work, how they are used alongside blood cancer treatments, and important safety considerations.

What corticosteroids are and how they work in the body

Corticosteroids like prednisone and dexamethasone are treatments designed to mimic hormones naturally produced by the adrenal glands, which sit above the kidneys. These hormones play important roles in the body's response to stress, inflammation, and immune system activity.

Corticosteroids work through both \"genomic\" and \"non-genomic\" pathways:

Genomic effects: Once inside a cell, corticosteroids bind to receptors and move into the nucleus to change how certain genes are expressed. This mainly decreases the production of inflammatory molecules.
Non-genomic effects: Corticosteroids can also act quickly at the cell membrane, blocking early stages of inflammation within minutes.

Understanding this is important because it explains why corticosteroids can act both rapidly and over time to control treatment-related symptoms.

Corticosteroids to support blood cancer treatments

Corticosteroids are used before or alongside cancer therapies. The benefits they provide include:

Reducing allergic-like reactions
Managing inflammation
Decreasing nausea and vomiting
Improving a poor appetite

This supportive use helps patients tolerate their blood cancer treatment better and maintain a higher quality of life.

Side effects and what patients should know

While corticosteroids are helpful, they also come with potential risks. Common side effects include:

Increased risk of infections
High blood sugar levels
Mood changes (such as anxiety or irritability)
Weight gain
Bone loss over time

The risk of these effects often depends on the dose and how long the medicine is taken. For people with blood cancers, this means that careful monitoring by your healthcare team is necessary. Special consideration may also be needed during treatments like CAR T-cell therapy, where research suggests corticosteroids at high doses for long periods of time should be limited to maintain treatment effectiveness.

Summary

Corticosteroids support blood cancer treatments by reducing inflammation and helping control immune responses. When given at the correct dose for the right amount of time, they can improve how well treatment is tolerated and symptoms are managed. Understanding their benefits and risks can help individuals and care teams make informed choices during the treatment process.

We need your help! Easily contribute to blood cancer research

If you are living with blood cancer, we need your help improving patient outcomes for all by taking simple, anonymous surveys that contribute to real-world research in HealthTree Cure Hub®. Click the button below to get started!

Make an Impact with Brief Blood Cancer Surveys

!AD!

Sources:

","language":"EN","metaDescription":"Learn how corticosteroids are used in blood cancer treatment, their benefits, and side effects to be aware of.","metaTitle":"How Are Steroids Used in Blood Cancer Treatment?","publishedAt":{"_type":"Date","value":"Tue Apr 29 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"corticosteroids in blood cancer, steroids leukemia treatment, steroids lymphoma therapy, prednisone blood cancer, dexamethasone blood cancer, blood cancer treatment support, steroids chemotherapy side effects, steroids inflammation management blood cancer","slug":"corticosteroids-use-blood-cancer-treatment","status":"ACTIVE","title":"How Are Steroids Used in Blood Cancer Treatment?","updatedAt":{"_type":"Date","value":"Wed Apr 30 2025 15:49:55 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/ZlMrOftm1a3LkZEvr50Z"},"snapshot":{"exists":true,"id":"ZlMrOftm1a3LkZEvr50Z","ref":{"_type":"DocumentReference","path":"apps/community/articles/ZlMrOftm1a3LkZEvr50Z"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/Yj5pk904HRNwZA8Wqfcu"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 21:04:47 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fpill_eca5ba08-73ec-4198-8434-11b9339d5926.webp%253Falt%253Dmedia","htmlContent":"

The excitement around menin inhibitors, a new class of targeted therapy for leukemia, is building. And for good reason: these new oral medications are showing promising results for patients with specific genetic changes in their leukemia cells.

\n
\"Menin inhibitors are a very exciting new type of therapy,\" explains Dr. Amer Zeidan, Professor of Medicine and Chief of Hematologic Malignancies at Yale University. \"They are pills that target specific alterations that occur in around 40% of patients with acute leukemia.\"
\n

A Treatment Twenty Years in the Making

The story of menin inhibitors began almost two decades ago, initially driven by pediatric oncologists seeking better treatments for infants with a particularly challenging type of acute lymphoblastic leukemia (ALL). Through years of careful research, scientists discovered that blocking the interaction between two proteins - menin and KMT2A - could force leukemia cells to mature into normal cells. This fundamental discovery has now led to a new class of treatments that could help both children and adults with certain types of leukemia.

What Are Menin Inhibitors and Who Could Benefit?

Menin inhibitors are targeted therapies - meaning they're designed to attack specific features of leukemia cells while largely sparing healthy cells. Your doctor might consider a menin inhibitor if your leukemia has specific genetic features:

NPM1 mutations: These are more common in younger patients and in those whose leukemia cells look normal under the microscope (what doctors call \"normal karyotype\"). About 30% of AML patients have this mutation.
KMT2A rearrangements: These occur in 5-10% of patients with acute leukemia. Your doctor might particularly suspect this if you've had previous chemotherapy for another cancer, especially breast cancer or lymphoma. These changes often occur in young children with ALL and in a type of AML where the leukemia cells look like monocytes (a type of white blood cell).

\n
\"Between these two alterations, around 40% of patients will have one of those changes. This targeted therapy follows the path of other targeted therapies we have used in AML, such as IDH inhibitors and FLT3 inhibitors,\" notes Dr. Zeidan.
\n

The Current Landscape: Multiple Menin Inhibitors in Development

Early clinical trials with different menin inhibitors are showing some consistent patterns:

About 60% of patients show some response to treatment
Around 25% or more achieve a complete remission
For those who respond, the benefits typically last about 6.5 months
Many patients who respond can proceed to stem cell transplant, which might provide longer-term control of their leukemia
The primary difference between menin inhibitors may be largely related to their safety profile

Several menin inhibitors are being studied:

Revumenib:

The first FDA-approved menin inhibitor (We'll have a detailed article about revumenib coming soon!)

Ziftomenib:

Combined with standard chemotherapy (7+3) in newly diagnosed AML patients
Impressive early results:\n
- Overall, 91% of patients responded to this treatment.
- The majority of patients (>80% in all subgroups) showed a complete remission of leukemia cells, including both NPM1-mutated patients and those with KMT2A rearrangements
- 76% of patients achieved MRD negativity (no detectable disease using sensitive testing)
\n

Based on the encouraging early results, there are now multiple trials underway investigating ziftomenib for both newly diagnosed and relapsed patients with acute leukemia. Additionally, an expanded access program has been established for patients with acute leukemia who have exhausted all other treatment options.

Bleximenib:

The latest results are from a study with 146 patients with relapsed/refractory acute leukemia, mostly AML\n
- Nearly 50% overall response rate, 38% of patients achieved complete remission, and 14% of patients were able to proceed to transplant so far, although the study is still ongoing
\n
When administered in combination with intensive chemotherapy to treat patients with newly diagnosed AML:\n
- Almost all patients quickly showed some level of response, and 86% achieved a complete remission
\n

Bleximenib is also moving forward in clinical development and is currently being studied in multiple clinical trials. The investigators shared that they are very excited to see these response rates, but that they are still on the learning curve with these agents and hypervigilant to make sure they are administered safely to patients who can benefit the most.

Enzomenib:

Enzomenib was designed to improve its specificity to hit its target, potentially reducing the side effects
It has shown activity both when administered alone and when combined with other medications
Response rates:\n
- 65.2% in KMT2A-rearranged leukemia
- 58.8% in NPM1-mutated leukemia
\n
Some patients (34% with KMT2A and 12% with NPM1) were able to proceed to allogeneic transplant
Notably, researchers did not have to alter the dose of enzomenib when prescribing an antifungal medication (also called an azole), which are frequently used to prevent infections in patients with leukemia.

Enzomenib is being studied in an international phase 1/2 study, which is still recruiting participants as of April 2025

What to Know About Menin Inhibitors Side Effects

While each menin inhibitor has its own safety profile, your healthcare team will help you monitor for and manage potential side effects. Here's what you need to know:

Differentiation Syndrome (DS):

Occurs in 10-15% of patients, and it is due to the rapid death of a large number of leukemia cells
Signs include: fever, breathing difficulties, fluid retention or swelling, rashes, low blood pressure, or even kidney failure

When treated early, it is manageable with temporary treatment interruption and steroids, so it is key that patients report any symptoms as soon as possible so the care team can treat them early.

Blood Count Changes:

Changes are common, especially when menin inhibitors are given in combination with chemotherapy
Patients take regular blood tests to monitor the cell counts
Significant changes in cell counts may lead to adjustments in the medication doses.

General Side Effects:

Nausea and vomiting (particularly with some agents)
Generally manageable with supportive care
Patients need to take their temperature twice daily

Managing Expectations

While the early results with menin inhibitors are encouraging, leading experts emphasize the importance of careful research. Experts are eagerly waiting for results from larger and randomized trials, which compare new treatments directly with current standards. These are essential to understand truly:

How long do responses last
Whether patients live longer with this treatment
Long-term side effects
Who benefits most from these treatments

\n
As Dr. Laura Michaelis from the Medical College of Wisconsin notes, \"All the data we have so far comes from non-comparative studies [there is no control arm]. We need to wait for randomized trials to really know the impact of these new treatments.\"
\n

Find Open Clinical Trials with Menin Inhibitors

\n
\"When you have a good drug that is active, you try to combine it in earlier lines of treatment with other standard of care treatments,\" explains Dr. Zeidan.
\n

This is exactly what's happening with menin inhibitors:

Studies combining them with standard chemotherapy
Trials with venetoclax and azacitidine combinations
Thoroughly being studied for newly diagnosed patients, relapsed/refractory, and also as maintenance after transplant

With HealthTree's Clinical Trial Finder, you can review all the clinical trials with menin inhibitors that are currently looking for patients with leukemia. If you connect your medical records, our Patient Navigators will also be able to assist you in understanding your eligibility to participate in these studies. Create a free Cure Hub account below and start exploring all your options:

Find Open Studies with Menin Inhibitors

Watch our full interview below with Dr. Zeidan, who discusses the latest menin inhibitor research.

What This Means for Patients

If you have AML or ALL, your doctor might test your leukemia cells for NPM1 mutations or KMT2A rearrangements. This testing helps determine if a menin inhibitor might be right for you now or in the future.

Remember: This is an exciting time in leukemia treatment, with new options becoming available for specific genetic changes. Talk to your healthcare team about whether genetic testing and menin inhibitors might be right for your situation.

!AD!

Continue learning about menin inhibitors from the experts. Click here to listen to Dr. Joshua Zeidner's experience with these revolutionary new treatments.

Continue Reading Leukemia News

Sources:

","language":"EN","metaDescription":"Learn about menin inhibitors, a new class of targeted treatments for leukemia patients with specific genetic changes.","metaTitle":"Menin Inhibitors for AML and ALL","publishedAt":{"_type":"Date","value":"Tue Apr 29 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"menin inhibitors leukemia, NPM1 mutation treatment, KMT2A rearrangement therapy, targeted leukemia therapy, leukemia targeted treatment, ziftomenib leukemia, bleximenib clinical trial, enzomenib leukemia, new leukemia treatments 2024, AML targeted therapy, leukemia oral treatment, leukemia clinical trials, NPM1 leukemia treatment, KMT2A leukemia therapy, ASH 2024, leukemia updates, leukemia mutation testing, menin inhibitor side effects, leukemia research advances, leukemia treatment options","slug":"menin-inhibitors-new-leukemia-treatment-option","status":"ACTIVE","title":"Menin Inhibitors: A New Treatment Option for Acute Leukemia Patients","updatedAt":{"_type":"Date","value":"Wed May 07 2025 16:35:52 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/VsqUhas0SAvEiOReodWy"},"snapshot":{"exists":true,"id":"VsqUhas0SAvEiOReodWy","ref":{"_type":"DocumentReference","path":"apps/community/articles/VsqUhas0SAvEiOReodWy"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Wed Apr 23 2025 22:38:21 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},"diseases":[{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fintravenous%252520drip%252520medication_e10ae69b-f737-4eb4-9c76-e92481f6e5a0.jpg%253Falt%253Dmedia","htmlContent":"

Vibecotamab is a type of antibody designed to target a specific protein called CD123, which is found in high levels on cancerous blood cells, especially those that affect the bone marrow’s ability to produce healthy blood cells (myeloid disorders). Because normal blood-forming cells have much lower levels of CD123, targeting this protein may help eliminate cancerous cells while sparing healthy ones.

A recent clinical study evaluated vibecotamab in patients with myeloid disorders who had limited treatment options. The study included patients with:

\n
Myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who have not responded to previous hypomethylating agents (azacitidine, decitabine).
\n
\n
Acute myeloid leukemia (AML) and in remission but with minimal residual disease (MRD) positive, meaning small amounts of leukemia cells remained in the body despite initial treatment.
\n

Key Study Findings

Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

68% of patients showed improvement
63% achieved complete remission, meaning cancerous cells were no longer detectable in the bone marrow
It is particularly telling that all 3 patients with CMML achieved a complete remission
The median duration of response was 5.2 months
Patients in the study lived for about 10 months on average after starting the treatment

Acute Myeloid Leukemia

28% of patients achieved MRD negativity, meaning there were no detectable leukemia cells in the bone marrow.
All responses happened within the first treatment cycle.
Some patients maintained their remission for over two years, while others relapsed after stopping treatment.
There was no connection between how likely someone was to respond and the amount of CD123 expressed in cancer cells.

What’s the Safety Profile of Vibecotamab?

Vibecotamab was considered by the researchers to be generally well tolerated
The most common side effect was infusion-related reactions, which were mostly mild to moderate
No patients had to stop treatment due to severe side effects
Unlike some other treatments, vibecotamab caused minimal suppression of healthy blood cell production

What This Means for Patients

The study suggests that vibecotamab may be beneficial for patients with limited treatment options, especially those with high-risk or relapsed disease. The findings suggest continuing vibecotamab beyond the initial treatment period may help maintain remission.

If you or a loved one is exploring new treatment options, it may be helpful to discuss new agents being tested in clinical trials. They can assess whether a new treatment like vibecotamab may be appropriate based on your specific condition, previous treatments, and overall health.

If you want to read more about treatment advances and clinical trial updates, bookmark the HealthTree News page to browse our articles, written just for you!

Keep Reading More Articles

","language":"EN","metaDescription":"Learn how vibecotamab targets CD123 to treat myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia.","metaTitle":" Vibecotamab for Myeloid Blood Cancers","publishedAt":{"_type":"Date","value":"Fri Apr 25 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"vibecotamab, CD123 antibody, myeloid blood cancer, myelodysplastic syndrome, MDS treatment, chronic myelomonocytic leukemia, CMML therapy, acute myeloid leukemia, AML treatment, minimal residual disease, leukemia research, targeted therapy, new cancer treatment, immunotherapy for leukemia, hematologic malignancies","slug":"ash-24-vibecotamab-for-cmml-aml-mds","status":"ACTIVE","title":"Vibecotamab: A Potential Treatment Option for Myeloid Blood Cancers","updatedAt":{"_type":"Date","value":"Wed Apr 23 2025 22:45:58 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/oTNkg66Dlkb4NWw3BxWv"},"snapshot":{"exists":true,"id":"oTNkg66Dlkb4NWw3BxWv","ref":{"_type":"DocumentReference","path":"apps/community/articles/oTNkg66Dlkb4NWw3BxWv"}}}],"categoryById":{"19hxT6XALz8ds00eORms":{"description":"Our Patient Stories articles contain patient and caregiver experiences, along with their advice for others going through similar circumstances.","metaDescription":"Read patient stories to learn about other’s experiences and what advice they have for people going through similar circumstances.","metaTitle":"Patient Stories - HealthTree Foundation","slug":"patient-stories","title":"Patient Stories"},"BnXIg7Ru4SK5FpscX41b":{"description":"Our HealthTree Research articles contain findings from surveys and studies inside HealthTree’s database. These surveys and studies are conducted by researchers and specialists.","metaDescription":"These articles are findings from HealthTree Research findings from surveys and studies.","metaTitle":"HealthTree Research - HealthTree Foundation","slug":"research","title":"HealthTree Research"},"MB3xw38fuKkx0LdszsrL":{"description":"Our Core Education articles help you understand your cancer so you are equipped to find a good care team, ask appropriate questions, and become your own best advocate.","metaDescription":"Learn 101 Education to help you know more about your cancer, what tests and treatments are available to you, and more.","metaTitle":"Core Education - HealthTree Foundation","slug":"core-education","title":"Core Education"},"SOL2ODcbaDI1CazQRbRS":{"description":"Read articles about HealthTree's progress in major media publications in video, online and in newspapers.","metaDescription":"These articles are about HealthTree's progress in major media publications in video, online and in newspapers.","metaTitle":"HealthTree Press - HealthTree Myeloma","slug":"healthtree-press","title":"HealthTree Press"},"WSTraX4hOKp92asdiTHa":{"description":"Our HealthTree Programs articles highlight the programs, events, and updates of the HealthTree Foundation.","metaDescription":"These articles highlight the programs, events, and updates of the HealthTree Foundation.","metaTitle":"HealthTree Programs - HealthTree Foundation","slug":"healthtree-programs","title":"HealthTree Programs"},"hUncpyMvyuZCF2qvA0Cv":{"description":"Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.","metaDescription":"These articles highlight top clinical trials, their results, and how patients can participate in them.","metaTitle":"Clinical Trials - HealthTree Foundation","slug":"clinical-trials","title":"Clinical Trials"},"haqKTOi9lG4MNU3rNLG6":{"description":"Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.","metaDescription":"It's important for patients to stay up-to-speed on advancements in their cancer because the treatment options are rapidly changing.","metaTitle":"Treatment Advances - HealthTree Foundation","slug":"treatment-advances","title":"Treatment Advances"},"hn1DyzeAyX6tgl3gxSDx":{"description":"Our Navigating Your Health articles can help you proactively take control of your health through wellness news, financial updates, healthy recipes, and more.","metaDescription":"Learn tips related to your overall wellness, including your mental, physical, and emotional health.","metaTitle":"Navigating Your Health - HealthTree Foundation","slug":"navigating-your-health","title":"Navigating Your Health"},"j4bWXiDzhdlhMFvaeXoc":{"description":"Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.","metaDescription":"These articles discuss the latest coverage of medical advancements from recent academic conferences.","metaTitle":"Conferences - HealthTree Foundation","slug":"conferences","title":"Conferences"}},"categoryIdBySlug":{"clinical-trials":"hUncpyMvyuZCF2qvA0Cv","conferences":"j4bWXiDzhdlhMFvaeXoc","core-education":"MB3xw38fuKkx0LdszsrL","healthtree-press":"SOL2ODcbaDI1CazQRbRS","healthtree-programs":"WSTraX4hOKp92asdiTHa","navigating-your-health":"hn1DyzeAyX6tgl3gxSDx","patient-stories":"19hxT6XALz8ds00eORms","research":"BnXIg7Ru4SK5FpscX41b","treatment-advances":"haqKTOi9lG4MNU3rNLG6"},"defaultMetaDescription":"Browse recent HealthTree articles and events focused on Acute Myeloid Leukemia. New site features, news articles, patient stories, Acute Myeloid Leukemia basics articles, and clinical trial updates.","defaultMetaTitle":"HealthTree Acute Myeloid Leukemia Articles - HealthTree for Acute Myeloid Leukemia","lastQueriedDoc":{"_type":"DocumentReference"},"reachedEnd":false,"trendingArticlesForWidget":[{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/Yj5pk904HRNwZA8Wqfcu"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 21:04:47 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fpill_eca5ba08-73ec-4198-8434-11b9339d5926.webp%253Falt%253Dmedia","htmlContent":"

\n
\"Menin inhibitors are a very exciting new type of therapy,\" explains Dr. Amer Zeidan, Professor of Medicine and Chief of Hematologic Malignancies at Yale University. \"They are pills that target specific alterations that occur in around 40% of patients with acute leukemia.\"
\n

A Treatment Twenty Years in the Making

What Are Menin Inhibitors and Who Could Benefit?

NPM1 mutations: These are more common in younger patients and in those whose leukemia cells look normal under the microscope (what doctors call \"normal karyotype\"). About 30% of AML patients have this mutation.
KMT2A rearrangements: These occur in 5-10% of patients with acute leukemia. Your doctor might particularly suspect this if you've had previous chemotherapy for another cancer, especially breast cancer or lymphoma. These changes often occur in young children with ALL and in a type of AML where the leukemia cells look like monocytes (a type of white blood cell).

\n
\"Between these two alterations, around 40% of patients will have one of those changes. This targeted therapy follows the path of other targeted therapies we have used in AML, such as IDH inhibitors and FLT3 inhibitors,\" notes Dr. Zeidan.
\n

The Current Landscape: Multiple Menin Inhibitors in Development

Early clinical trials with different menin inhibitors are showing some consistent patterns:

About 60% of patients show some response to treatment
Around 25% or more achieve a complete remission
For those who respond, the benefits typically last about 6.5 months
Many patients who respond can proceed to stem cell transplant, which might provide longer-term control of their leukemia
The primary difference between menin inhibitors may be largely related to their safety profile

Several menin inhibitors are being studied:

Revumenib:

The first FDA-approved menin inhibitor (We'll have a detailed article about revumenib coming soon!)

Ziftomenib:

Combined with standard chemotherapy (7+3) in newly diagnosed AML patients
Impressive early results:\n
- Overall, 91% of patients responded to this treatment.
- The majority of patients (>80% in all subgroups) showed a complete remission of leukemia cells, including both NPM1-mutated patients and those with KMT2A rearrangements
- 76% of patients achieved MRD negativity (no detectable disease using sensitive testing)
\n

Bleximenib:

The latest results are from a study with 146 patients with relapsed/refractory acute leukemia, mostly AML\n
- Nearly 50% overall response rate, 38% of patients achieved complete remission, and 14% of patients were able to proceed to transplant so far, although the study is still ongoing
\n
When administered in combination with intensive chemotherapy to treat patients with newly diagnosed AML:\n
- Almost all patients quickly showed some level of response, and 86% achieved a complete remission
\n

Enzomenib:

Enzomenib was designed to improve its specificity to hit its target, potentially reducing the side effects
It has shown activity both when administered alone and when combined with other medications
Response rates:\n
- 65.2% in KMT2A-rearranged leukemia
- 58.8% in NPM1-mutated leukemia
\n
Some patients (34% with KMT2A and 12% with NPM1) were able to proceed to allogeneic transplant
Notably, researchers did not have to alter the dose of enzomenib when prescribing an antifungal medication (also called an azole), which are frequently used to prevent infections in patients with leukemia.

Enzomenib is being studied in an international phase 1/2 study, which is still recruiting participants as of April 2025

What to Know About Menin Inhibitors Side Effects

While each menin inhibitor has its own safety profile, your healthcare team will help you monitor for and manage potential side effects. Here's what you need to know:

Differentiation Syndrome (DS):

Occurs in 10-15% of patients, and it is due to the rapid death of a large number of leukemia cells
Signs include: fever, breathing difficulties, fluid retention or swelling, rashes, low blood pressure, or even kidney failure

When treated early, it is manageable with temporary treatment interruption and steroids, so it is key that patients report any symptoms as soon as possible so the care team can treat them early.

Blood Count Changes:

Changes are common, especially when menin inhibitors are given in combination with chemotherapy
Patients take regular blood tests to monitor the cell counts
Significant changes in cell counts may lead to adjustments in the medication doses.

General Side Effects:

Nausea and vomiting (particularly with some agents)
Generally manageable with supportive care
Patients need to take their temperature twice daily

Managing Expectations

How long do responses last
Whether patients live longer with this treatment
Long-term side effects
Who benefits most from these treatments

\n
As Dr. Laura Michaelis from the Medical College of Wisconsin notes, \"All the data we have so far comes from non-comparative studies [there is no control arm]. We need to wait for randomized trials to really know the impact of these new treatments.\"
\n

Find Open Clinical Trials with Menin Inhibitors

\n
\"When you have a good drug that is active, you try to combine it in earlier lines of treatment with other standard of care treatments,\" explains Dr. Zeidan.
\n

This is exactly what's happening with menin inhibitors:

Studies combining them with standard chemotherapy
Trials with venetoclax and azacitidine combinations
Thoroughly being studied for newly diagnosed patients, relapsed/refractory, and also as maintenance after transplant

Find Open Studies with Menin Inhibitors

Watch our full interview below with Dr. Zeidan, who discusses the latest menin inhibitor research.

What This Means for Patients

!AD!

Continue learning about menin inhibitors from the experts. Click here to listen to Dr. Joshua Zeidner's experience with these revolutionary new treatments.

Continue Reading Leukemia News

Sources:

","language":"EN","metaDescription":"Learn about menin inhibitors, a new class of targeted treatments for leukemia patients with specific genetic changes.","metaTitle":"Menin Inhibitors for AML and ALL","publishedAt":{"_type":"Date","value":"Tue Apr 29 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"menin inhibitors leukemia, NPM1 mutation treatment, KMT2A rearrangement therapy, targeted leukemia therapy, leukemia targeted treatment, ziftomenib leukemia, bleximenib clinical trial, enzomenib leukemia, new leukemia treatments 2024, AML targeted therapy, leukemia oral treatment, leukemia clinical trials, NPM1 leukemia treatment, KMT2A leukemia therapy, ASH 2024, leukemia updates, leukemia mutation testing, menin inhibitor side effects, leukemia research advances, leukemia treatment options","slug":"menin-inhibitors-new-leukemia-treatment-option","status":"ACTIVE","title":"Menin Inhibitors: A New Treatment Option for Acute Leukemia Patients","updatedAt":{"_type":"Date","value":"Wed May 07 2025 16:35:52 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/VsqUhas0SAvEiOReodWy"},"snapshot":{"exists":true,"id":"VsqUhas0SAvEiOReodWy","ref":{"_type":"DocumentReference","path":"apps/community/articles/VsqUhas0SAvEiOReodWy"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/haqKTOi9lG4MNU3rNLG6"},"createdAt":{"_type":"Date","value":"Mon Mar 31 2025 21:57:56 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_2505283421_b49db66a-742e-4542-9d33-40687e871ef3.jpg%253Falt%253Dmedia","htmlContent":"

ImmunoGen, a pharmaceutical company, recently announced the findings for a new AML therapy for newly diagnosed patients, currently in phase 1b/2. In this article, we compiled the information on this new therapy that is out so far.

Pivekimab sunirine (IMGN632) is an innovative antibody-drug conjugate (ADC) designed to target CD123, a protein found in AML cells and other blood cancers. This medication delivers potent anti-leukemic effects with fewer side effects on normal marrow cells. The results of using pivekimab sunirine both as a monotherapy in relapsed or refractory AML, and in combination therapy with azacitidine and venetoclax for newly diagnosed AML patients, have been promising so far.

Pivekimab sunirine as a single therapy for relapsed or refractory AML patients

The study is currently active but does not recruit patients. It aims to assess the safety and tolerability of this medication. 91 patients were enrolled, with an overall response rate (ORR) of 21% and a complete remission rate of 17%.

Common treatment-related adverse events included febrile neutropenia, infusion reactions, and anemia. These results led to further investigation in a phase 1b/2 study, where pivekimab was combined with azacitidine and venetoclax in newly diagnosed AML patients.

Triple therapy for newly diagnosed AML patients: pivekimab sunirine, azacitidine, and venetoclax

The combination, known as the “pivekimab triplet,” demonstrated encouraging response rates, including high rates of minimal residual disease (MRD) negativity associated with deeper remission.

In this study, patients received:

pivekimab 0.045 mg/kg on day 7
azacitidine on days 1-7
venetoclax for 14 to 28 days per 28-day cycle
54% of patients achieved a complete response (CR)
76% of patients had MRD negativity.
Patients with TP53 mutations also had high response rates, achieving a complete response rate of 88% and an MRD negativity rate of 80%.

The side effects were the usual ones reported with azacitidine and venetoclax (low platelets, bruising, gum bleeding). Other side effects included constipation, swelling, and nausea, and only 4% of patients discontinued due to adverse events.

Looking forward to updates and FDA Review

In conclusion, ImmunoGen's development of pivekimab sunirine (IMGN632) marks a significant advance in AML therapy, particularly for newly diagnosed patients and those with high-risk genetic mutations, such as TP53. The combination of pivekimab sunirine with azacitidine and venetoclax shows potential for deeper remissions, as reflected in the phase 1b/2 trial.

While side effects were manageable, the high response rates seen in even the more complex cases show that it can provide a positive impact in future AML treatment protocols. As we await the release of further data, pivekimab sunirine continues to hold promise as a targeted and effective treatment option for AML patients.

Keep track of your health with HealthTree CureHub!

If you are interested in tracking your labs and staying on top of your health by exploring all our free resources, you can create a free HealthTree account!

CREATE MY FREE ACCOUNT

Sources:

","language":"EN","metaDescription":" ImmunoGen’s pivekimab sunirine shows high response rates in AML, especially with azacitidine and venetoclax. ","metaTitle":"New AML Therapy: Pivekimab Sunirine ","publishedAt":{"_type":"Date","value":"Mon Mar 31 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"aml, pivekimab sunirine, ImmunoGen, CD123 antibody, AML phase 1b, azacitidine, venetoclax, AML remission, TP53 mutation","slug":"pivekimab-sunirine-for-aml","status":"ACTIVE","title":"New AML Therapy: Pivekimab Sunirine","updatedAt":{"_type":"Date","value":"Mon Mar 31 2025 22:09:58 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/6fV5dtVSvI3KKBSNSrLo"},"snapshot":{"exists":true,"id":"6fV5dtVSvI3KKBSNSrLo","ref":{"_type":"DocumentReference","path":"apps/community/articles/6fV5dtVSvI3KKBSNSrLo"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/jBpDWkHVhDQGjBwBMUzk"},"category":{"_type":"DocumentReference","path":"apps/community/categories/j4bWXiDzhdlhMFvaeXoc"},"createdAt":{"_type":"Date","value":"Fri Mar 28 2025 22:50:32 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FScreen%252520Shot%2525202023-07-20%252520at%25252012.11.19%252520PM_85d1d490-90bb-4519-a3b0-b174902abde0.png%253Falt%253Dmedia","htmlContent":"

For older patients over the age of 75 or those who can’t receive intensive chemotherapy, the combination of venetoclax with a hypomethylating agent (Ven/HMA) offers a highly effective alternative. However, the long-term curative potential of this regimen remains uncertain.

Dr. Andrew Zale, resident at The Johns Hopkins Hospital, shared the findings of a retrospective study at the 66th annual ASH conference. This study focused on NPM1-mutated AML patients without FLT3-ITD mutations, and theorized that their AML can be cured with intensive chemotherapy alone.

A retrospective analysis compared overall survival (OS) between patients with favorable-risk NPM1-mutated AML treated with either intensive chemotherapy or venetoclax combined with a hypomethylating agent. The study analyzed 55 patients, aged 60 to 75, from the Johns Hopkins institutional database and used advanced statistical methods to evaluate survival outcomes and contributing factors.

Key Study Findings

Patients treated with intensive chemotherapy were younger and more likely to have undergone treatment before the FDA approved venetoclax
A higher proportion of patients, 69%, underwent transplantation at first remission
Response and Survival Outcomes: Response rates were similar between the two groups. Median overall survival was 6.2 years for the intensive chemotherapy group compared to 4.9 years for the Ven/HMA group.
Factors Influencing Survival:\n
- Higher baseline white blood cell counts were associated with worse survival outcomes
- Transplantation in first remission significantly improved survival
\n

Among Ven/HMA-treated patients who underwent transplantation (37%), survival outcomes were excellent. None experienced a relapse, and only one patient passed due to non-relapse causes.

Takeaway Message

For patients aged 60 to 75 with favorable-risk NPM1-mutated AML, both intensive chemotherapy and venetoclax/hypomethylating agents can offer comparable responses, which can lead to eligibility for stem cell transplant and ultimately, comparable survival outcomes. Choosing between these therapies depends on the patient’s characteristics and individual preferences.

This analysis emphasizes the importance of tailoring treatment decisions to the unique circumstances of each patient. It also highlights the need for alternative therapy options that further improve outcomes, as well as next-generation sequencing for measurable residual disease testing. These findings provide valuable guidance for patients and caregivers navigating treatment options and underscore the evolving landscape of AML management.

Learn More With HealthTree!

If you are interested in keeping up to date with more AML news you can bookmark the HealthTree News site, and explore other interesting and comprehensive articles, made just for you!

Keep Reading More News

","language":"EN","metaDescription":"Learn about survival outcomes for older NPM1-mutated AML patients treated with chemotherapy or venetoclax and hypomethylating agents.","metaTitle":"Treatment Insights for NPM1-Mutated AML Patients","publishedAt":{"_type":"Date","value":"Wed Apr 02 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"NPM1-mutated AML, AML survival outcomes, venetoclax treatment, hypomethylating agents, Johns Hopkins study, AML treatment options, AML intensive chemotherapy, AML patient care, favorable-risk AML, AML research findings","slug":"ash-24-intensive-chemo-vs-hma-for-aml","status":"ACTIVE","title":"What Works Better for AML: Intensive Chemotherapy or Venetoclax/HMAs?","updatedAt":{"_type":"Date","value":"Fri Mar 28 2025 23:27:59 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/S551cSujhuSJI4tN4AGx"},"snapshot":{"exists":true,"id":"S551cSujhuSJI4tN4AGx","ref":{"_type":"DocumentReference","path":"apps/community/articles/S551cSujhuSJI4tN4AGx"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/Y1TeubuOek8X0mlZ691N"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 19:11:41 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fcachexia_dd4d620b-edae-4c23-891c-79e1b4e9d566.jpg%253Falt%253Dmedia","htmlContent":"

When you or a loved one is diagnosed with acute myeloid leukemia (AML), understanding how the cancer affects the body becomes crucial. A recent study of 565 AML patients has revealed important insights about a condition called cachexia that can significantly impact treatment outcomes.

What is Cancer Cachexia?

Cancer cachexia is much more than ordinary weight loss. It's a complex condition that affects how your body maintains muscle and fat, how you feel about eating, and even how your body uses the energy from food. Your body's response to cancer triggers these changes in three main ways:

Cancer cells release signals that cause muscle and fat loss, even if you're eating well
Your appetite often decreases, leading to reduced food intake
Your body's metabolism changes, making it harder to use glucose (sugar) for energy

How Cachexia Can Affect AML Treatment Outcomes?

What the Research Tells Us

A comprehensive study followed AML patients with a median age of 67 years through their treatment journey. The researchers used something called the Weight Loss Grading Scale (WLGS) to track how cachexia affected patients over time. Here's what they discovered:

During treatment:

About one-third of patients (31%) showed significant weight loss at 3 months
This number decreased to 19% by the 12-month mark

These findings become particularly meaningful when we look at survival rates. Patients with more severe weight loss (grade 3 or higher) had a median survival time of 16.4 months, while those with less weight loss typically survived for about 25.7 months. Interestingly, the study found that while weight loss affected survival, it didn't significantly impact how quickly the disease might return (relapse time).

Cachexia Can Affect Results Regardless of Treatment Type

The study included patients receiving various types of treatment, including:

Chemotherapy only (58%)
Combinations of chemotherapy with targeted agents (36%)
Other (6%)

This diverse treatment background helps us understand how cachexia affects patients regardless of their specific treatment plan.

What This Means for You

If you're dealing with AML, these findings suggest that paying attention to weight changes, especially in the first three months of treatment, could be crucial. Here's what you can do:

Monitor your weight regularly
Keep your healthcare team informed about any changes
Work with a nutritionist who understands cancer care
Discuss your risk factors with your doctor, especially if you have intermediate or high-risk AML

Looking Ahead

While these findings might seem concerning, they're helping doctors better understand how to care for AML patients. Future studies are exploring whether adding specific treatments for cachexia might help improve outcomes, especially for patients with higher-risk disease.

!AD!

Join Our Community

At HealthTree, we want to make sure you have all the information you need to make decisions about your care and better navigate your disease. Through our free educational webinars and support resources, you can:

Learn from leading AML experts
Connect with other patients who understand your journey
Stay updated on the latest research
Access practical tips for managing your condition

Whether you're newly diagnosed or well into your treatment journey, understanding cachexia is an important part of managing AML. By staying informed and working closely with your healthcare team, you can better advocate for your health and potentially improve your treatment outcomes.

Want to learn more or share your experience? Join our next webinar or connect with our supportive community.

Explore Upcoming AML Webinars

Source:

The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia

","language":"EN","metaDescription":"Learn how cancer cachexia affects AML survival rates, what new research reveals about weight loss, and practical steps to manage this condition.","metaTitle":"Weight Loss & Survival in AML","publishedAt":{"_type":"Date","value":"Thu Apr 17 2025 06:00:00 GMT+0000 (Coordinated Universal Time)"},"seoKeywords":"AML cachexia, acute myeloid leukemia weight loss, cancer cachexia survival, AML patient guide, cancer weight loss management, AML treatment outcomes, cachexia symptoms, AML survival rates, cancer nutrition support, weight loss grading scale, AML patient resources, cancer metabolism changes, leukemia support groups, AML research 2025, cancer weight management, AML patient care, cancer cachexia treatment, HealthTree AML resources, leukemia cachexia symptoms, AML patient education","slug":"aml-cancer-cachexia-survival","status":"ACTIVE","title":"Understanding Cancer Cachexia and Its Impact on AML Survival","updatedAt":{"_type":"Date","value":"Wed Apr 23 2025 22:25:07 GMT+0000 (Coordinated Universal Time)"}},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/articles/aUdOAarj6x3gqXx4lYVU"},"snapshot":{"exists":true,"id":"aUdOAarj6x3gqXx4lYVU","ref":{"_type":"DocumentReference","path":"apps/community/articles/aUdOAarj6x3gqXx4lYVU"}}},{"data":{"author":{"_type":"DocumentReference","path":"apps/community/authors/dtN24frUcPS1CRElyXh1"},"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"createdAt":{"_type":"Date","value":"Fri Apr 18 2025 19:03:22 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/cll"},"diseases":[{"_type":"DocumentReference","path":"diseases/1NJgYv1SwmEhehLIL0Pz"},{"_type":"DocumentReference","path":"diseases/EkjGB5kileTKP2vnTWhV"},{"_type":"DocumentReference","path":"diseases/GMiulNhUPGrzlsCN3Fmv"},{"_type":"DocumentReference","path":"diseases/GxAhXAnh3drV4xY5Vf3A"},{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},{"_type":"DocumentReference","path":"diseases/WGt6OKKh829p4KeZXIgE"},{"_type":"DocumentReference","path":"diseases/WNjIFmDibXhTFneCh4dG"},{"_type":"DocumentReference","path":"diseases/YQLqL1ObFAc03K5Thpvx"},{"_type":"DocumentReference","path":"diseases/anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/angioimmunoblastic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/b-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/blastic-plasmacytoid-dendritic-cell-neoplasm"},{"_type":"DocumentReference","path":"diseases/burkitts-lymphoma"},{"_type":"DocumentReference","path":"diseases/chronic-myelomonocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/cll"},{"_type":"DocumentReference","path":"diseases/cutaneous-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/eBIxYtdHAYhTTs5L9bcC"},{"_type":"DocumentReference","path":"diseases/enteropathy-associated-intestinal-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/essential-thrombocythemia"},{"_type":"DocumentReference","path":"diseases/extranodal-natural-killer"},{"_type":"DocumentReference","path":"diseases/hairy-cell-leukemia"},{"_type":"DocumentReference","path":"diseases/hepatosplenic-t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/large-granular-lymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/leukemia"},{"_type":"DocumentReference","path":"diseases/lymphoblastic-lymphoma"},{"_type":"DocumentReference","path":"diseases/lymphoma"},{"_type":"DocumentReference","path":"diseases/mantle-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/marginal-zone-lyphoma"},{"_type":"DocumentReference","path":"diseases/mastocytosis"},{"_type":"DocumentReference","path":"diseases/mediastinal-b-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/mucosa-associated-lymphoid-tissue-lymphoma"},{"_type":"DocumentReference","path":"diseases/my-app"},{"_type":"DocumentReference","path":"diseases/myeloproliferative-neoplasm"},{"_type":"DocumentReference","path":"diseases/non-hodgkin-lymphoma"},{"_type":"DocumentReference","path":"diseases/peripheral-t-cell-lyphoma"},{"_type":"DocumentReference","path":"diseases/polycythemia-vera"},{"_type":"DocumentReference","path":"diseases/qfJSwjR5sHYmyCKUCUjA"},{"_type":"DocumentReference","path":"diseases/systemic-anaplastic-large-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-lymphoma"},{"_type":"DocumentReference","path":"diseases/t-cell-prolymphocytic-leukemia"},{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"diseases/tDYO4O8HTJT5dAHT6xis"},{"_type":"DocumentReference","path":"diseases/w5T0uo4aL9LHbseGyhym"},{"_type":"DocumentReference","path":"diseases/waldenströms-macroglobulinemia"}],"headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fshutterstock_2139857171_d14928f5-f612-4043-98be-81af536978c2.jpg%253Falt%253Dmedia","htmlContent":"

How Blood Cancer Treatments and Other Risk Factors May Impact Brain Function

Several factors can contribute to changes in brain function as a result of blood cancer treatment.

The treatments themselves, like chemotherapy, targeted therapy, radiation, and immunotherapy, can affect brain health by:

Crossing the barrier that protects your brain and directly impacting brain cells.
Triggering inflammation through immune system activation, which clouds brain function.
Remaining oxidative stress after treatment—caused by too many free radicals and not enough antioxidants—can damage healthy cells and trigger inflammation, affecting areas like the brain.

Factors That Increase Your Risk

Even without treatment, cancer cells can increase inflammation in the body, which may dampen brain function.

What Do Symptoms Look Like?

The brain-related symptoms you may experience from certain blood cancer treatments may include:

Mild to moderate symptoms: trouble thinking clearly, confusion, fatigue, headaches
More serious issues (rare): difficulty speaking, tremors, seizures

Tips for Recovery

If your brain-related symptoms aren’t improving over time, it’s important to get help. Here are some supportive strategies:

Consult with your blood cancer specialist: Talk to your doctor about ways to manage treatment side effects. For example, if you're experiencing headaches from a cancer therapy, ask what can help. They might recommend adding a headache-relief medication, adjusting the dose, or switching to a different treatment.
Nutrition support: Work with a registered dietitian to reduce inflammation and address nutrient gaps that directly impact brain health.
Visit a functional neurologist: See a functional neurologist who can pinpoint which areas of your brain need support and create a personalized therapy plan using targeted eye, hand, or balance exercises to help strengthen them. They may also suggest adding certain medications. This differs from a neurologist, who focuses mostly on medication to treat symptoms.
Mental health support: A licensed therapist can help you manage stress, anxiety, or trauma, and teach coping skills—like mindfulness and breathing techniques—that may reduce inflammation and improve your quality of life.
Lifestyle habits: Getting enough sleep, staying hydrated, exercising moderately, and eating nutrient-dense foods can support brain health.

Key Takeaways

Brain-related side effects from blood cancer treatments can occur and range from mild brain fog to more serious neurological issues.

Even if side effects are expected, working closely with your care team is key to finding the right solutions for your cognitive health and overall well-being.

Discover Patient-Reported Side Effect Solutions

Access Side Effect Solutions

!AD!

Sources:

Marilú introduces the agenda for the event and featured speaker Dr Terra Lasho

","id":"list_ae396b8a_b7d1_4533_b829_4248d798c0a8","title":"Introduction"},{"agendaPanelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/3ZuAoRVjuGInoq5CEVAQ"},"blockDateTime":{"day":"1","time":{"hours":"3","meridiem":"PM","minutes":"05"}},"customSpeaker":false,"description":"

Dr. Terra talks about VEXAS Syndrome

","id":"list_e708997b_b825_4836_a9f2_14c566ceb992","speaker":null,"title":"Presentation"},{"agendaPanelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/FznD9UfFKvnTrZvKUg19"},"blockDateTime":{"day":"1","time":{"hours":"3","meridiem":"PM","minutes":"35"}},"description":"

Type your questions in the chat and we will answer them!

\n","id":"list_71a37f17_b3a7_4bc7_9cf3_f338324daeea","title":"Questions and Answers"}],"allowAttendeeQuestions":true,"attendeesReminder":[0,1,24],"category":{"_type":"DocumentReference","path":"apps/community/categories/hn1DyzeAyX6tgl3gxSDx"},"chapter":{"_type":"DocumentReference","path":"apps/community/chapters/dmg5qURn58IMSXAvDJzT"},"createdAt":{"_type":"Date","value":"Tue Mar 19 2024 20:20:52 GMT+0000 (Coordinated Universal Time)"},"disease":{"_type":"DocumentReference","path":"diseases/WCJo8IouncjDW6exT1YS"},"diseases":[{"_type":"DocumentReference","path":"diseases/t8f3E99OdM9XZe1d1ASM"}],"endDate":{"datetime":{"_type":"Date","value":"Wed Jun 04 2025 20:00:00 GMT+0000 (Coordinated Universal Time)"},"timezone":"America/New_York"},"eventCategory":{"_type":"DocumentReference","path":"apps/community/eventCategories/P6erGoRrTLWnLdOgff33"},"eventFormat":"WEBINAR","eventManager":{"_type":"DocumentReference","path":"users/zSJP9G3GQoOG4DMXkFm6Vt3qOwo1"},"eventRecap":[{"id":"list_9c464c7d_f058_4f6c_9c30_941654b26cec","recapContent":"

Jimena begins by explaining the essentials of lab tracking for myelodysplastic syndrome (MDS), covering key tests like complete blood count (CBC), blast percentages, and genetic markers, offering patients a comfortable starting point to understand the most important lab results.

","title":"Starting Your Lab Tracking Journey"},{"id":"list_da798b50_c8d2_4421_8f7f_b12239b3bb8f","recapContent":"

Regular tracking isn’t just a habit—it’s a way to stay one step ahead. Jimena emphasizes how consistent lab tracking can reveal trends that allow patients and doctors to anticipate changes, helping to proactively adjust care plans as patients’ needs evolve.

","title":"Monitoring Your Lab Trends Over Time"},{"id":"list_f2e55da0_6846_4778_a056_d40ad0151179","recapContent":"

Jimena shares practical tips on how to make lab tracking a smooth part of daily life, recommending tools like our HealthTree Cure Hub Registry where you can keep your labs organized and help patients to track their lab results easily.

","title":"Setting Up a Lab Tracking System That Works for You"},{"id":"list_e536756f_417c_427d_84c5_1397ec595d33","recapContent":"

Jimena encourages open, proactive communication with healthcare providers, underscoring the importance of patients asking questions to understand their results fully. By fostering this partnership, patients can become stronger advocates for their health.

","title":"Strengthening Your Dialogue with Your Care Team"},{"id":"list_28db09fe_25cb_4edf_888b_26d709608c08","recapContent":"

Jimena closes with an encouraging reminder that lab tracking is more than a medical exercise—it’s a way for patients to actively manage and feel empowered in their MDS journey. Then, Marilu explains a bit more about our tool, HealthTree Cure Hub Registry, and how patients can benefit from using it to track their labs.

","title":"Lab Tracking as a Step Toward Empowerment"},{"id":"list_393595c4_df39_4844_b362_45799a2a46c5","recapContent":"

During the Q&A session, Jimena answered questions from the community, and Marilu shared more details about our HealthTree Cure Hub app. To view the full recording, sign in to your HealthTree account and click the \"Watch Recording\" button above.

The Q&A begins at 25:10. Here are the questions raised:

[25:10] \"What is the importance of knowing the type of MDS?\"
[26:30] \"Are there alternative tests that might reduce the need for a biopsy?\"
[27:52] \"Marilu explains more about HealthTree Cure Hub.\"

","title":" Q&A Recap: Key Questions from the Audience"}],"eventRecapHeader":"Event Highlights","eventRecapStatus":"DRAFT","eventType":"ZOOM_MEETING","headerImageUrl":"https://healthtree.org/images-resize?imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252Fportrait%252520young%252520asian%252520dermatologist%252520_77153fd3-25f7-458a-817b-50e9473f947d.jpg%253Falt%253Dmedia","htmlDescription":"

Being diagnosed with a condition like VEXAS syndrome can raise a lot of questions, especially when it’s discussed alongside myelodysplastic syndromes (MDS). In this webinar, we’ll help you understand what VEXAS syndrome is, how it may be connected to MDS, and what symptoms and diagnosis may look like. We’ll also explore possible treatment options and how to navigate care. Whether you’ve been diagnosed, are looking for answers, or simply want to learn more, this session is here to guide and support you.

","intercomTagName":"Event: 5-27-2025 - Acute Myeloid Leukemia - What is VEXAS syndrome and how is it related to MDS?","isPrivate":false,"maxAttendees":0,"metaDescription":"In this webinar, we’ll help you understand what VEXAS syndrome is, how it may be connected to MDS, and what symptoms and diagnosis may look like.","metaTitle":"VEXAS syndrome and how is it related to MDS","migratedReason":"global-community","migratedReason2":"fix global-community categories","oldCategory":{"_type":"DocumentReference","path":"apps/community/categories/egKoeye54V84f9M2YzLT"},"panelistSpeakers":[{"id":"list_10ec94d1_cba4_4e44_9c6e_cedf8c942cd4","panelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/5Qp3J1par5AnbV752iPu"}},{"id":"list_c7ef155a_a4fa_4d2b_a891_b6a6766ee014","panelist":{"_type":"DocumentReference","path":"apps/community/eventPanelists/3ZuAoRVjuGInoq5CEVAQ"}}],"primaryConnectGroup":{"_type":"DocumentReference","path":"apps/connect/connectGroups/bRjyW1hG2p7bST9OK2WA"},"publishedAt":{"_type":"Date","value":"Fri Mar 15 2024 07:00:00 GMT+0000 (Coordinated Universal Time)"},"recorded":true,"recordingType":"PUBLIC","secondaryConnectGroups":[{"_type":"DocumentReference","path":"apps/connect/connectGroups/general-t8f3E99OdM9XZe1d1ASM"},{"_type":"DocumentReference","path":"apps/connect/connectGroups/ASiKTytBW34lSauw8R0U"},{"_type":"DocumentReference","path":"apps/connect/connectGroups/8wYH4KOs3PIfcuQxLdKU"}],"sentEventAvailableEmail":false,"seoKeywords":"myelodysplastic syndromes, mds, vexas syndrome, diagnosis, newly diagnosed, relapsed refractory patients","slug":"june2025-myelodysplastic-syndromes-vexas","startDate":{"datetime":{"_type":"Date","value":"Wed Jun 04 2025 19:00:00 GMT+0000 (Coordinated Universal Time)"},"timezone":"America/New_York"},"status":"ACTIVE","title":"What is VEXAS syndrome and how is it related to MDS?","topic":{"_type":"DocumentReference","path":"apps/community/topics/jJ7chBlCu7HyDQpzZyKG"},"totalEventAttendees":1,"totalInPersonAttendees":0,"totalVirtualAttendees":0,"updatedAt":{"_type":"Date","value":"Thu May 08 2025 20:23:08 GMT+0000 (Coordinated Universal Time)"},"zoomJoinUrl":"https://us06web.zoom.us/j/89043913823","zoomMeetingId":89043913823,"zoomStartUrl":"https://us06web.zoom.us/s/89043913823?zak=eyJ0eXAiOiJKV1QiLCJzdiI6IjAwMDAwMiIsInptX3NrbSI6InptX28ybSIsImFsZyI6IkhTMjU2In0.eyJpc3MiOiJ3ZWIiLCJjbHQiOjAsIm1udW0iOiI4OTA0MzkxMzgyMyIsImF1ZCI6ImNsaWVudHNtIiwidWlkIjoiUDhOc3V2dVlUXzZrSGtLbWZnTEZDdyIsInppZCI6ImIwYzBjN2JlMWYxZDQwNWJiODQzMzAzNWUyNGYwZWI4Iiwic2siOiIwIiwic3R5IjoxMDAsIndjZCI6InVzMDYiLCJleHAiOjE3NDU5MTA2NDYsImlhdCI6MTc0NTkwMzQ0NiwiYWlkIjoiVnEwc0ZHTUlTTmFxMVpqN3QyZ3ZWQSIsImNpZCI6IiJ9.uC7Pnx2QsgNZ1mCu7-uxEPNr3ImwdlzPpjByBrrlyzg"},"included":{},"ref":{"_type":"DocumentReference","path":"apps/community/events/8UZ1ykG1GSRp3kmfsBBV"},"snapshot":{"exists":true,"id":"8UZ1ykG1GSRp3kmfsBBV","ref":{"_type":"DocumentReference","path":"apps/community/events/8UZ1ykG1GSRp3kmfsBBV"}}}]}